for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

67.81USD

Change

0.00(0.00%)

Volume

8,639,754

Today's Range

67.77

 - 

69.31

52 Week Range

61.39

 - 

74.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
67.81
Open
69.07
Volume
8,639,754
3M AVG Volume
149.78
Today's High
69.31
Today's Low
67.77
52 Week High
74.12
52 Week Low
61.39
Shares Out (MIL)
1,254.38
Market Cap (MIL)
86,640.27
Forward P/E
8.55
Dividend (Yield %)
4.11

Next Event

Q4 2021 Gilead Sciences Inc Earnings Release

Latest Developments

More

Gilead Announces Actions To Remove Counterfeit HIV Medications From U.S. Supply Chain

Gilead Announces Clinical Trial Collaborations With Merck

Gilead Sciences - Brett A. Pletcher Plans To Retire From Position As Executive Vice President, Corporate Affairs, General Counsel & Corporate Secretary

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

FOSTER CITY, CA

94404

United States

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew D. Dickinson

Chief Financial Officer

Flavius Martin

Executive Vice President - Research

Johanna Mercier

Chief Commercial Officer

Merdad V. Parsey

Chief Medical Officer

Key Stats

2.48 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

22.1K

2019

22.4K

2020

24.7K

2021(E)

26.6K
EPS (USD)

2018

6.670

2019

6.630

2020

7.090

2021(E)

8.101
Price To Earnings (TTM)
11.82
Price To Sales (TTM)
3.15
Price To Book (MRQ)
4.04
Price To Cash Flow (TTM)
9.19
Total Debt To Equity (MRQ)
128.95
LT Debt To Equity (MRQ)
117.26
Return on Investment (TTM)
13.62
Return on Equity (TTM)
11.52

Latest News

Latest News

Gilead says counterfeit HIV drugs ended up with patients

Gilead Sciences Inc said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years, endangering patients.

Gilead withdraws use of Zydelig to treat two types of cancer

Gilead Sciences Inc on Friday notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia.

Gilead withdraws use of Zydelig to treat two types of cancer

Gilead Sciences Inc has notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia. (Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)

Russia extends production of COVID-19 drug remdesivir without patent for a year

The Russian government extended on Thursday its approval for drugmaker Pharmasyntez to produce a generic version of U.S. anti-COVID-19 drug remdesivir without a patent for one year, citing the need to protect its citizens.

Gilead sues Lupin over proposed generic of Symtuza HIV drug

Gilead Sciences Inc has said an Indian generic drugmaker's proposed version of the HIV drug Symtuza infringes its patents, in a lawsuit in Delaware federal court.

Gilead trims 2021 sales forecast for non-COVID products

Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.

Gilead beats profit expectations on COVID-19 drug sales

Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings as strong demand for its COVID-19 antiviral treatment, Veklury, offset flagging sales of its HIV drugs.

Gilead Sciences wins reversal of $1.2 billion award in patent case with Bristol Myers

(Corrects paragraph 1 and 2 to show one patent, not patents)

REFILE-Gilead Sciences wins reversal of $1.2 bln fine against Bristol Myers in patent case

Gilead Sciences Inc escaped a $1.2 billion fine, after the Federal Circuit Court of Appeals on Thursday found the relevant parts of a Bristol Myers Squibb patent that Gilead's Yescarta cancer drug allegedly infringed were invalid.

Gilead to require U.S. workers receive COVID-19 vaccine

Gilead Sciences Inc said on Monday it will require all its employees and contractors in the United States to become vaccinated against COVID-19.

Gilead says aware of counterfeit HIV medicines being distributed in U.S.

Gilead Sciences said on Thursday it has become aware that tampered and counterfeit versions of its HIV treatments, Biktarvy and Descovy, are in circulation within U.S. drug distribution networks.

Lilly's COVID-19 drug reduces death risk in patients on mechanical ventilation

Eli Lilly and Co and partner Incyte Corp said on Tuesday additional results from a late-stage study showed their COVID-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation.

Gilead's COVID-19 drug helps boost 2nd-quarter results as HIV sales dip

Gilead Sciences Inc on Thursday posted a higher-than-expected second-quarter profit, helped by strong demand for its COVID-19 antiviral treatment, Veklury, but sales of its flagship HIV drugs lagged as the pandemic continued to limit visits to doctors.

Strong COVID-19 drug sales help boost Gilead second-quarter results

Gilead Sciences Inc on Thursday posted higher second-quarter earnings, helped by strong sales of its COVID-19 antiviral treatment, Veklury, as well as hepatitis drugs.

U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir

The U.S. health regulator expanded the emergency use authorization for Eli Lilly's COVID-19 drug baricitinib, saying it could now be used without taking Gilead's drug remdesivir along with it, Lilly said on Thursday.

BioNTech strengthens cancer therapy expertise with U.S. acquisition

BioNTech said it was acquiring a production site and a research and development platform from a subsidiary of U.S. biotech company Gilead to expand its footprint in north America and in novel cancer treatments.

Unauthorized COVID-19 drugs bound for Mexico seized by U.S. authorities - WSJ

Federal authorities have seized at U.S. airports unauthorized versions of the COVID-19 treatment remdesivir destined for distribution in Mexico, the Wall Street Journal reported on Wednesday.

Gilead's remdesivir reduces COVID-19 mortality risk- data

Gilead Sciences Inc said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalized patients with COVID-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.

Russian court rejects U.S firm's lawsuit over COVID-19 drug remdesivir

Russia's Supreme Court on Thursday rejected a lawsuit from U.S. company Gilead Sciences that challenged a Russian government decision to let a Russian firm develop and market the anti-COVID-19 drug remdesivir without Gilead's consent.

Russian Supreme Court rejects Gilead lawsuit over COVID-19 drug

Russia's Supreme Court on Thursday rejected a lawsuit from U.S. company Gilead Sciences challenging the Russian government's decision last year to let a Russian pharmaceutical firm develop the COVID-19 drug remdesivir without Gilead's consent.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up